Groundbreaking Nipocalimab Study of Pregnant Individuals at High Risk for Early Onset Severe Hemolytic Disease of the Fetus and Newborn Published in The New England Journal of Medicine
Groundbreaking Nipocalimab Study of Pregnant Individuals at High Risk for Early Onset Severe Hemolytic Disease of the Fetus and Newborn Published in The New England Journal of Medicine
《新英格兰医学杂志》发表的孕期高危早发严重胎儿溶血症的开创性Nipocalimab研究
Nipocalimab delayed or prevented severe fetal anemia and 54 percent of study participants in the Phase 2 UNITY study achieved a live birth at or after 32 weeks without the need for intrauterine transfusion (IUT)
The AZALEA Phase 3 clinical study is currently enrolling patients: Nipocalimab is the only therapy in clinical development for use in pregnancies at risk for severe hemolytic disease of the fetus and newborn (HDFN)
Nipocalimab 延缓或预防了严重的胎儿贫血，在 2 期 UNITY 研究中，54% 的研究参与者在 32 周或之后无需宫内输血 (IUT) 就实现了活产
AZALEA 3期临床研究目前正在招收患者：Nipocalimab是临床开发中唯一一种用于有严重胎儿和新生儿溶血性疾病（HDFN）风险的妊娠的疗法
资讯热榜
更新时间